Skip to content

Study · Not a test of the peptide alone · 2026

5 results

Use of a Serum With the Infinite Glow® Device Improves Signs of Facial Aging: A Split-Face Case Report Using VISIA Analysis.

Rodríguez D, Rodríguez M, Andersen C

Cureus23 Jun 2026

PMID42500768 (opens in a new tab)PMCIDPMC13399947 (opens in a new tab)DOI10.7759/cureus.111375 (opens in a new tab)PepBankPUB-42500768
Download PDFPubMedAsk about this study
Jump to 5 results

Summary

An increase in wrinkles, laxity, and dyschromia characterizes facial-skin aging. The skin is a natural barrier that prevents or limits the entry of external therapeutic compounds to the body. Enhancing the efficacy of transdermal delivery of anti-aging compounds is a key therapeutic strategy. The study aimed to evaluate the efficacy and safety of a combined therapy that included a topical anti-aging serum and a multi-technology facial device designed to improve transdermal absorption. A 41-year-old woman with moderate facial aging was treated using a split-face design for 12 weeks. Every day, the left hemiface received a hyaluronic acid-niacinamide-Matrixyl serum. In contrast, the right hemiface received the same serum plus application of a multi-therapy device that delivered red light (630 nm), galvanic current, micro-vibration, and controlled heat. Skin changes were assessed using the VISIA Skin Analysis System (Canfield Scientific, Parsippany, New Jersey) at baseline, 6, and 12 weeks. Both hemifaces showed improvement in skin quality parameters (wrinkles, texture, and UV spots). TruSkin age decreased by five years on the treated side with the device + serum and by one year on the serum-only side. Greater improvement in wrinkle reduction was observed on the device-treated side. No adverse events were reported. As a preliminary observation, combined therapy using a topical serum and a multimodal device appears safe and attenuates aging effects, particularly in reducing wrinkles. Further studies are needed to confirm these findings.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Matrixyl (palmitoyl pentapeptide-4).

  1. 01HumanNot a test of Matrixyl (palmitoyl pentapeptide-4) aloneCase report or seriesEfficacy outcome

    In one woman, both serum-treated hemifaces improved in skin quality parameters, with and without the device.

    In plain wordsIn one woman, skin quality improved on both serum-treated sides, with and without the device.

    Peptide
    Matrixyl (palmitoyl pentapeptide-4)
    Outcome
    IncreaseSkin quality parameters
    Study

    n = 1

    Outcome group
    Skin and hair · Skin and wound

    Source sentences

    Summary
    Both hemifaces showed improvement in skin quality parameters (wrinkles, texture, and UV spots).
    1 context sentence
    Summary · context
    A 41-year-old woman with moderate facial aging was treated using a split-face design for 12 weeks. Every day, the left hemiface received a hyaluronic acid-niacinamide-Matrixyl serum. In contrast, the right hemiface received the same serum plus application of a multi-therapy device that delivered red light (630 nm), galvanic current, micro-vibration, and controlled heat.

    In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Matrixyl (palmitoyl pentapeptide-4).

  2. 02HumanNot a test of Matrixyl (palmitoyl pentapeptide-4) aloneCase report or seriesEfficacy outcome

    In one woman, device plus hyaluronic acid-niacinamide-Matrixyl serum reduced TruSkin age by five years.

    In plain wordsIn one woman, the device plus serum reduced measured skin age by five years.

    Peptide
    Matrixyl (palmitoyl pentapeptide-4)
    Outcome
    DecreaseTruSkin age with device and serum
    Study

    n = 1

    Outcome group
    Skin and hair · Skin and wound

    Measurements

    TruSkin age decrease
    5 years
    hemiface treated with device + serum

    Source sentences

    Summary
    TruSkin age decreased by five years on the treated side with the device + serum and by one year on the serum-only side.
    1 context sentence
    Summary · context
    A 41-year-old woman with moderate facial aging was treated using a split-face design for 12 weeks. Every day, the left hemiface received a hyaluronic acid-niacinamide-Matrixyl serum. In contrast, the right hemiface received the same serum plus application of a multi-therapy device that delivered red light (630 nm), galvanic current, micro-vibration, and controlled heat.

    In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Matrixyl (palmitoyl pentapeptide-4).

  3. 03HumanNot a test of Matrixyl (palmitoyl pentapeptide-4) aloneCase report or seriesEfficacy outcome

    In one woman, hyaluronic acid-niacinamide-Matrixyl serum alone reduced TruSkin age by one year.

    In plain wordsIn one woman, serum alone reduced measured skin age by one year.

    Peptide
    Matrixyl (palmitoyl pentapeptide-4)
    Outcome
    DecreaseTruSkin age with serum alone
    Study

    n = 1

    Outcome group
    Skin and hair · Skin and wound

    Measurements

    TruSkin age decrease
    1 years
    serum-only hemiface

    Source sentences

    Summary
    TruSkin age decreased by five years on the treated side with the device + serum and by one year on the serum-only side.
    1 context sentence
    Summary · context
    A 41-year-old woman with moderate facial aging was treated using a split-face design for 12 weeks. Every day, the left hemiface received a hyaluronic acid-niacinamide-Matrixyl serum. In contrast, the right hemiface received the same serum plus application of a multi-therapy device that delivered red light (630 nm), galvanic current, micro-vibration, and controlled heat.

    In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Matrixyl (palmitoyl pentapeptide-4).

  4. 04HumanNot a test of Matrixyl (palmitoyl pentapeptide-4) aloneCase report or seriesEfficacy outcome

    In one woman, device plus serum reduced wrinkles more than serum alone.

    In plain wordsIn one woman, the device plus serum reduced wrinkles more than serum alone.

    Peptide
    Matrixyl (palmitoyl pentapeptide-4)
    Outcome
    DecreaseWrinkle reduction
    Study

    n = 1

    Comparator
    Same serum without device
    Outcome group
    Skin and hair · Skin and wound

    Source sentences

    Summary
    Greater improvement in wrinkle reduction was observed on the device-treated side.
    1 context sentence
    Summary · context
    A 41-year-old woman with moderate facial aging was treated using a split-face design for 12 weeks. Every day, the left hemiface received a hyaluronic acid-niacinamide-Matrixyl serum. In contrast, the right hemiface received the same serum plus application of a multi-therapy device that delivered red light (630 nm), galvanic current, micro-vibration, and controlled heat.

    In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Matrixyl (palmitoyl pentapeptide-4).

  5. 05HumanNot a test of Matrixyl (palmitoyl pentapeptide-4) aloneCase report or seriesSafety outcome

    In one woman using serum with and without the device, no adverse events were reported.

    In plain wordsIn one woman using serum with and without the device, no adverse events were reported.

    Peptide
    Matrixyl (palmitoyl pentapeptide-4)
    Outcome
    Direction not reportedAdverse events
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    No adverse events were reported.
    1 context sentence
    Summary · context
    A 41-year-old woman with moderate facial aging was treated using a split-face design for 12 weeks. Every day, the left hemiface received a hyaluronic acid-niacinamide-Matrixyl serum. In contrast, the right hemiface received the same serum plus application of a multi-therapy device that delivered red light (630 nm), galvanic current, micro-vibration, and controlled heat.

    In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Matrixyl (palmitoyl pentapeptide-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.